Skip to content
Subscriber Only

Stryker Biotech Marketing Put Patients at Risk, U.S. Says

A unit of Stryker Corp., the maker of medical devices, and three former sales managers put patients at risk by marketing an unapproved mixture of products for strengthening human bone growth, a prosecutor said at the start of a federal criminal trial in Boston.

The U.S. has charged Hopkinton, Massachusetts-based Stryker Biotech with misbranding and its sales force with conspiring to defraud surgeons into combining the company’s OP-1 and OP-1 Putty with the bone filler Calstrux. Some patients suffered adverse side effects and required more surgery, the U.S. says.